Literature DB >> 8733091

Cost benefit analysis of single and dual chamber pacing for sick sinus syndrome and atrioventricular block. An economic sensitivity analysis of the literature.

R Sutton1, I Bourgeois.   

Abstract

The benefits of dual (DDD) over single chamber pacing (VVI) have been demonstrated in haemodynamics, exercise capacity, quality of life and reduced complications in atrioventricular block and sick sinus syndrome. The literature was reviewed to provide complication rates for dual and VVI pacing. Cost calculations were based on United Kingdom 1991 prices. Over a 10-year period, a computer model calculated the incidence and prevalence of atrial fibrillation, stroke, permanent disability, heart failure and mortality in six patient categories: sick sinus syndrome paced VVI, sick sinus syndrome upgraded to DDD, sick sinus syndrome paced DDD from outset, atrioventricular block paced VVI and those upgraded to DDD and atrioventricular block paced initially DDD. Calculations were based on intention to treat. The 10 year survival with DDD vs VVI pacing was 71% vs 57% in sick sinus syndrome and 61% vs 51%, respectively, in atrioventricular block. In both indications the prevalence of heart failure in the 10 year survivors was 60% lower with DDD pacing. In sick sinus syndrome patients paced VVI, 36% had severe disability while only 8% experienced this with DDD pacing. For atrioventricular block the figures were, respectively, 22% vs 3%. The difference in 10 year cumulative cost between VVI and DDD is 13 times the purchase price of a VVI pulse generator for sick sinus syndrome and 7 times for atrioventricular block. In the third year after implantation the cumulative costs of DDD were lower than for VVI for both indications. Dual chamber pacing for both indications, sick sinus syndrome and atrioventricular block, is both clinically and cost effective.

Entities:  

Mesh:

Year:  1996        PMID: 8733091     DOI: 10.1093/oxfordjournals.eurheartj.a014911

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  6 in total

Review 1.  Endocavitary treatment of atrial fibrillation.

Authors:  S B Olsson; E I Hertervig; O Kongstad; C Meurling; S Yuan
Journal:  J Thromb Thrombolysis       Date:  1999-01       Impact factor: 2.300

2.  Impact of continuous quality improvement on selection of pacing mode and rate of complications in permanent pacing.

Authors:  J E Møller; E H Simonsen; M Møller
Journal:  Heart       Date:  1997-04       Impact factor: 5.994

3.  Systematic trial of pacing to prevent atrial fibrillation (STOP-AF).

Authors:  R G Charles; J M McComb
Journal:  Heart       Date:  1997-09       Impact factor: 5.994

4.  Cryoablation of stellate ganglia and atrial arrhythmia in ambulatory dogs with pacing-induced heart failure.

Authors:  Masahiro Ogawa; Alex Y Tan; Juan Song; Kenzaburo Kobayashi; Michael C Fishbein; Shien-Fong Lin; Lan S Chen; Peng-Sheng Chen
Journal:  Heart Rhythm       Date:  2009-08-13       Impact factor: 6.343

5.  Is Mobitz type I atrioventricular block benign in adults?

Authors:  D B Shaw; J I Gowers; C A Kekwick; K H J New; A W T Whistance
Journal:  Heart       Date:  2004-02       Impact factor: 5.994

6.  Single chamber atrial pacing: an underused and cost-effective pacing modality in sinus node disease.

Authors:  K W Clarke; D T Connelly; R G Charles
Journal:  Heart       Date:  1998-10       Impact factor: 5.994

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.